Pharvaris director reports initial share holdings

Pharvaris N.V. director Johannes Schikan reports his beneficial holdings in the company.

Rhea-AI Filing Summary

Pharvaris N.V. director Johannes Schikan reports his beneficial holdings in the company. He directly holds 395,167 shares of Common Stock, which includes restricted stock units that will settle in common shares.

He also holds several stock options to buy common shares, including 16,500 shares at an exercise price of $28.0000 per share expiring in 2036, 15,000 shares at $16.0500 expiring in 2035, 14,000 shares at $22.3100 expiring in 2034, 21,000 shares at $8.0500 expiring in 2033, 17,500 shares at $18.1400 expiring in 2032, and 35,000 shares at $20.0000 expiring in 2031. A grant of 5,500 restricted stock units from March 3, 2026 is scheduled to vest on March 3, 2027.

Insider Trade Summary

7 transactions reported

Mixed 7 txns

Insider Schikan Johannes Gerardus Christiaan Petrus

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 119,000 contracts (Direct); Common Stock — 395,167 shares (Direct)

Footnotes (5)

1. F1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027.
2. F2. 100% of the option vest on the 12-month anniversary.
3. F3. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
4. F4. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.
5. F5. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Pharvaris (PHVS) Form 3 filing for Johannes Schikan show?

The Form 3 shows director Johannes Schikan’s current holdings in Pharvaris N.V., including 395,167 shares of Common Stock and multiple stock option awards, giving investors a clear view of his existing equity exposure and potential future share ownership through option exercises and RSU vesting.

How many Pharvaris (PHVS) common shares does Johannes Schikan hold?

Johannes Schikan directly holds 395,167 shares of Pharvaris Common Stock. This figure includes restricted stock units that will settle in common shares, reflecting his total reported non-derivative equity interest as of the Form 3 filing date for this initial ownership report.

What stock options in Pharvaris (PHVS) does Johannes Schikan report?

He reports several stock option grants to buy Pharvaris Common Stock, including 16,500 shares at $28.0000, 15,000 at $16.0500, 14,000 at $22.3100, 21,000 at $8.0500, 17,500 at $18.1400 and 35,000 at $20.0000, expiring between 2031 and 2036.

When do Johannes Schikan’s Pharvaris (PHVS) restricted stock units vest?

A grant of 5,500 restricted stock units to Johannes Schikan, awarded on March 3, 2026, is scheduled to vest in full on March 3, 2027. These RSUs settle in Pharvaris common shares and are counted within his reported non-derivative holdings.

Does the Pharvaris (PHVS) Form 3 show any recent insider buying or selling?

The Form 3 does not report new purchases or sales; it lists existing holdings. All entries are categorized as holdings, detailing Schikan’s current common stock position, outstanding restricted stock units, and unexercised stock options with their exercise prices and expiration dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 02:23 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Schikan Johannes Gerardus Christiaan Petrus

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/17/2026

3. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	395,167(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	03/03/2027(2)	03/03/2036	Common Stock	16,500	$28	D
Stock Option (Right to Buy)	03/12/2026(2)	03/12/2035	Common Stock	15,000	$16.05	D
Stock Option (Right to Buy)	04/11/2025(2)	04/11/2034	Common Stock	14,000	$22.31	D
Stock Option (Right to Buy)	(3)	04/06/2033	Common Stock	21,000	$8.05	D
Stock Option (Right to Buy)	(4)	04/01/2032	Common Stock	17,500	$18.14	D
Stock Option (Right to Buy)	(5)	02/05/2031	Common Stock	35,000	$20	D

Explanation of Responses:

1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027.

2. 100% of the option vest on the 12-month anniversary.

3. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

4. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

5. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Johannes Schikan	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)